Global Phenylketonuria
Global Phenylketonuria

Phenylketonuria Comprehensive Study by Type (Classic, Mild, Benign), Treatment (Drug Therapy, Dietary Therapy, Gene Therapy), Test (Diagnostic Test, Screening Test), End User (Household, Hospital, Others) Players and Region - Global Market Outlook to 2024

Phenylketonuria Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

Oct 2019 Edition 227 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Phenylketonuria Market Definition
Phenylketonuria (PKU) is an inborn error of metabolism that results in decreased metabolism of the amino acid phenylalanine. Untreated PKU can lead to intellectual disability, seizures, behavioral problems, and mental disorders. It may also result in a musty smell and lighter skin. Babies born to mothers who have poorly treated PKU may have heart problems, a small head, and low birth weight.

The market study is broken down by Type (Classic, Mild and Benign) and major geographies with country level splits.

Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Phenylketonuria market throughout the predicted period.

Agios Pharmaceuticals Inc. (United States), BioMarin Pharmaceutical Inc. (United States), Nestlé Health Science (Switzerland), American Gene Technologies International Inc (United States), Mead Johnson & Company, LLC. (United States), Danone Nutricia (Netherlands), Ajinomoto Cambrooke, Inc. (United States), Dr. Schär (Italy), Promin Metabolics (United States) and PKU Perspectives (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Censa Pharmaceuticals Inc. (United States) and Erytech Pharma SA (France).

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Phenylketonuria market by Type, Application and Region.

On the basis of geography, the market of Phenylketonuria has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment, the sub-segment i.e. Drug Therapy will boost the Phenylketonuria market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Test, the sub-segment i.e. Diagnostic Test will boost the Phenylketonuria market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Household will boost the Phenylketonuria market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.




Market Drivers
  • Rising Number of Newborn Who Suffers from the Phenylketonuria
  • Increasing Healthcare Spending and Rising Healthcare Infrastructure in Developing Economies

Opportunities
  • Increasing Awareness about the Phenylketonuria Disease among the People Creates the Opportunities for Market

Restraints
  • Issues Related to Screening of Newborn are hindering the Market


About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Classic
  • Mild
  • Benign
By Treatment
  • Drug Therapy
  • Dietary Therapy
  • Gene Therapy

By Test
  • Diagnostic Test
  • Screening Test

By End User
  • Household
  • Hospital
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Number of Newborn Who Suffers from the Phenylketonuria
      • 3.2.2. Increasing Healthcare Spending and Rising Healthcare Infrastructure in Developing Economies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Phenylketonuria, by Type, Treatment, Test, End User and Region (value) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Phenylketonuria (Value)
      • 5.2.1. Global Phenylketonuria by: Type (Value)
        • 5.2.1.1. Classic
        • 5.2.1.2. Mild
        • 5.2.1.3. Benign
      • 5.2.2. Global Phenylketonuria by: Treatment (Value)
        • 5.2.2.1. Drug Therapy
        • 5.2.2.2. Dietary Therapy
        • 5.2.2.3. Gene Therapy
      • 5.2.3. Global Phenylketonuria by: Test (Value)
        • 5.2.3.1. Diagnostic Test
        • 5.2.3.2. Screening Test
      • 5.2.4. Global Phenylketonuria by: End User (Value)
        • 5.2.4.1. Household
        • 5.2.4.2. Hospital
        • 5.2.4.3. Others
      • 5.2.5. Global Phenylketonuria Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Phenylketonuria: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Agios Pharmaceuticals Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. BioMarin Pharmaceutical Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Nestlé Health Science (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. American Gene Technologies International Inc (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Mead Johnson & Company, LLC. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Danone Nutricia (Netherlands)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Ajinomoto Cambrooke, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Dr. Schär (Italy)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Promin Metabolics (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. PKU Perspectives (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Phenylketonuria Sale, by Type, Treatment, Test, End User and Region (value) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Phenylketonuria (Value)
      • 7.2.1. Global Phenylketonuria by: Type (Value)
        • 7.2.1.1. Classic
        • 7.2.1.2. Mild
        • 7.2.1.3. Benign
      • 7.2.2. Global Phenylketonuria by: Treatment (Value)
        • 7.2.2.1. Drug Therapy
        • 7.2.2.2. Dietary Therapy
        • 7.2.2.3. Gene Therapy
      • 7.2.3. Global Phenylketonuria by: Test (Value)
        • 7.2.3.1. Diagnostic Test
        • 7.2.3.2. Screening Test
      • 7.2.4. Global Phenylketonuria by: End User (Value)
        • 7.2.4.1. Household
        • 7.2.4.2. Hospital
        • 7.2.4.3. Others
      • 7.2.5. Global Phenylketonuria Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Phenylketonuria: by Type(USD Million)
  • Table 2. Phenylketonuria Classic , by Region USD Million (2013-2018)
  • Table 3. Phenylketonuria Mild , by Region USD Million (2013-2018)
  • Table 4. Phenylketonuria Benign , by Region USD Million (2013-2018)
  • Table 5. Phenylketonuria: by Treatment(USD Million)
  • Table 6. Phenylketonuria Drug Therapy , by Region USD Million (2013-2018)
  • Table 7. Phenylketonuria Dietary Therapy , by Region USD Million (2013-2018)
  • Table 8. Phenylketonuria Gene Therapy , by Region USD Million (2013-2018)
  • Table 9. Phenylketonuria: by Test(USD Million)
  • Table 10. Phenylketonuria Diagnostic Test , by Region USD Million (2013-2018)
  • Table 11. Phenylketonuria Screening Test , by Region USD Million (2013-2018)
  • Table 12. Phenylketonuria: by End User(USD Million)
  • Table 13. Phenylketonuria Household , by Region USD Million (2013-2018)
  • Table 14. Phenylketonuria Hospital , by Region USD Million (2013-2018)
  • Table 15. Phenylketonuria Others , by Region USD Million (2013-2018)
  • Table 16. South America Phenylketonuria, by Country USD Million (2013-2018)
  • Table 17. South America Phenylketonuria, by Type USD Million (2013-2018)
  • Table 18. South America Phenylketonuria, by Treatment USD Million (2013-2018)
  • Table 19. South America Phenylketonuria, by Test USD Million (2013-2018)
  • Table 20. South America Phenylketonuria, by End User USD Million (2013-2018)
  • Table 21. Brazil Phenylketonuria, by Type USD Million (2013-2018)
  • Table 22. Brazil Phenylketonuria, by Treatment USD Million (2013-2018)
  • Table 23. Brazil Phenylketonuria, by Test USD Million (2013-2018)
  • Table 24. Brazil Phenylketonuria, by End User USD Million (2013-2018)
  • Table 25. Argentina Phenylketonuria, by Type USD Million (2013-2018)
  • Table 26. Argentina Phenylketonuria, by Treatment USD Million (2013-2018)
  • Table 27. Argentina Phenylketonuria, by Test USD Million (2013-2018)
  • Table 28. Argentina Phenylketonuria, by End User USD Million (2013-2018)
  • Table 29. Rest of South America Phenylketonuria, by Type USD Million (2013-2018)
  • Table 30. Rest of South America Phenylketonuria, by Treatment USD Million (2013-2018)
  • Table 31. Rest of South America Phenylketonuria, by Test USD Million (2013-2018)
  • Table 32. Rest of South America Phenylketonuria, by End User USD Million (2013-2018)
  • Table 33. Asia Pacific Phenylketonuria, by Country USD Million (2013-2018)
  • Table 34. Asia Pacific Phenylketonuria, by Type USD Million (2013-2018)
  • Table 35. Asia Pacific Phenylketonuria, by Treatment USD Million (2013-2018)
  • Table 36. Asia Pacific Phenylketonuria, by Test USD Million (2013-2018)
  • Table 37. Asia Pacific Phenylketonuria, by End User USD Million (2013-2018)
  • Table 38. China Phenylketonuria, by Type USD Million (2013-2018)
  • Table 39. China Phenylketonuria, by Treatment USD Million (2013-2018)
  • Table 40. China Phenylketonuria, by Test USD Million (2013-2018)
  • Table 41. China Phenylketonuria, by End User USD Million (2013-2018)
  • Table 42. Japan Phenylketonuria, by Type USD Million (2013-2018)
  • Table 43. Japan Phenylketonuria, by Treatment USD Million (2013-2018)
  • Table 44. Japan Phenylketonuria, by Test USD Million (2013-2018)
  • Table 45. Japan Phenylketonuria, by End User USD Million (2013-2018)
  • Table 46. India Phenylketonuria, by Type USD Million (2013-2018)
  • Table 47. India Phenylketonuria, by Treatment USD Million (2013-2018)
  • Table 48. India Phenylketonuria, by Test USD Million (2013-2018)
  • Table 49. India Phenylketonuria, by End User USD Million (2013-2018)
  • Table 50. South Korea Phenylketonuria, by Type USD Million (2013-2018)
  • Table 51. South Korea Phenylketonuria, by Treatment USD Million (2013-2018)
  • Table 52. South Korea Phenylketonuria, by Test USD Million (2013-2018)
  • Table 53. South Korea Phenylketonuria, by End User USD Million (2013-2018)
  • Table 54. Taiwan Phenylketonuria, by Type USD Million (2013-2018)
  • Table 55. Taiwan Phenylketonuria, by Treatment USD Million (2013-2018)
  • Table 56. Taiwan Phenylketonuria, by Test USD Million (2013-2018)
  • Table 57. Taiwan Phenylketonuria, by End User USD Million (2013-2018)
  • Table 58. Australia Phenylketonuria, by Type USD Million (2013-2018)
  • Table 59. Australia Phenylketonuria, by Treatment USD Million (2013-2018)
  • Table 60. Australia Phenylketonuria, by Test USD Million (2013-2018)
  • Table 61. Australia Phenylketonuria, by End User USD Million (2013-2018)
  • Table 62. Rest of Asia-Pacific Phenylketonuria, by Type USD Million (2013-2018)
  • Table 63. Rest of Asia-Pacific Phenylketonuria, by Treatment USD Million (2013-2018)
  • Table 64. Rest of Asia-Pacific Phenylketonuria, by Test USD Million (2013-2018)
  • Table 65. Rest of Asia-Pacific Phenylketonuria, by End User USD Million (2013-2018)
  • Table 66. Europe Phenylketonuria, by Country USD Million (2013-2018)
  • Table 67. Europe Phenylketonuria, by Type USD Million (2013-2018)
  • Table 68. Europe Phenylketonuria, by Treatment USD Million (2013-2018)
  • Table 69. Europe Phenylketonuria, by Test USD Million (2013-2018)
  • Table 70. Europe Phenylketonuria, by End User USD Million (2013-2018)
  • Table 71. Germany Phenylketonuria, by Type USD Million (2013-2018)
  • Table 72. Germany Phenylketonuria, by Treatment USD Million (2013-2018)
  • Table 73. Germany Phenylketonuria, by Test USD Million (2013-2018)
  • Table 74. Germany Phenylketonuria, by End User USD Million (2013-2018)
  • Table 75. France Phenylketonuria, by Type USD Million (2013-2018)
  • Table 76. France Phenylketonuria, by Treatment USD Million (2013-2018)
  • Table 77. France Phenylketonuria, by Test USD Million (2013-2018)
  • Table 78. France Phenylketonuria, by End User USD Million (2013-2018)
  • Table 79. Italy Phenylketonuria, by Type USD Million (2013-2018)
  • Table 80. Italy Phenylketonuria, by Treatment USD Million (2013-2018)
  • Table 81. Italy Phenylketonuria, by Test USD Million (2013-2018)
  • Table 82. Italy Phenylketonuria, by End User USD Million (2013-2018)
  • Table 83. United Kingdom Phenylketonuria, by Type USD Million (2013-2018)
  • Table 84. United Kingdom Phenylketonuria, by Treatment USD Million (2013-2018)
  • Table 85. United Kingdom Phenylketonuria, by Test USD Million (2013-2018)
  • Table 86. United Kingdom Phenylketonuria, by End User USD Million (2013-2018)
  • Table 87. Netherlands Phenylketonuria, by Type USD Million (2013-2018)
  • Table 88. Netherlands Phenylketonuria, by Treatment USD Million (2013-2018)
  • Table 89. Netherlands Phenylketonuria, by Test USD Million (2013-2018)
  • Table 90. Netherlands Phenylketonuria, by End User USD Million (2013-2018)
  • Table 91. Rest of Europe Phenylketonuria, by Type USD Million (2013-2018)
  • Table 92. Rest of Europe Phenylketonuria, by Treatment USD Million (2013-2018)
  • Table 93. Rest of Europe Phenylketonuria, by Test USD Million (2013-2018)
  • Table 94. Rest of Europe Phenylketonuria, by End User USD Million (2013-2018)
  • Table 95. MEA Phenylketonuria, by Country USD Million (2013-2018)
  • Table 96. MEA Phenylketonuria, by Type USD Million (2013-2018)
  • Table 97. MEA Phenylketonuria, by Treatment USD Million (2013-2018)
  • Table 98. MEA Phenylketonuria, by Test USD Million (2013-2018)
  • Table 99. MEA Phenylketonuria, by End User USD Million (2013-2018)
  • Table 100. Middle East Phenylketonuria, by Type USD Million (2013-2018)
  • Table 101. Middle East Phenylketonuria, by Treatment USD Million (2013-2018)
  • Table 102. Middle East Phenylketonuria, by Test USD Million (2013-2018)
  • Table 103. Middle East Phenylketonuria, by End User USD Million (2013-2018)
  • Table 104. Africa Phenylketonuria, by Type USD Million (2013-2018)
  • Table 105. Africa Phenylketonuria, by Treatment USD Million (2013-2018)
  • Table 106. Africa Phenylketonuria, by Test USD Million (2013-2018)
  • Table 107. Africa Phenylketonuria, by End User USD Million (2013-2018)
  • Table 108. North America Phenylketonuria, by Country USD Million (2013-2018)
  • Table 109. North America Phenylketonuria, by Type USD Million (2013-2018)
  • Table 110. North America Phenylketonuria, by Treatment USD Million (2013-2018)
  • Table 111. North America Phenylketonuria, by Test USD Million (2013-2018)
  • Table 112. North America Phenylketonuria, by End User USD Million (2013-2018)
  • Table 113. United States Phenylketonuria, by Type USD Million (2013-2018)
  • Table 114. United States Phenylketonuria, by Treatment USD Million (2013-2018)
  • Table 115. United States Phenylketonuria, by Test USD Million (2013-2018)
  • Table 116. United States Phenylketonuria, by End User USD Million (2013-2018)
  • Table 117. Canada Phenylketonuria, by Type USD Million (2013-2018)
  • Table 118. Canada Phenylketonuria, by Treatment USD Million (2013-2018)
  • Table 119. Canada Phenylketonuria, by Test USD Million (2013-2018)
  • Table 120. Canada Phenylketonuria, by End User USD Million (2013-2018)
  • Table 121. Mexico Phenylketonuria, by Type USD Million (2013-2018)
  • Table 122. Mexico Phenylketonuria, by Treatment USD Million (2013-2018)
  • Table 123. Mexico Phenylketonuria, by Test USD Million (2013-2018)
  • Table 124. Mexico Phenylketonuria, by End User USD Million (2013-2018)
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Phenylketonuria: by Type(USD Million)
  • Table 136. Phenylketonuria Classic , by Region USD Million (2019-2024)
  • Table 137. Phenylketonuria Mild , by Region USD Million (2019-2024)
  • Table 138. Phenylketonuria Benign , by Region USD Million (2019-2024)
  • Table 139. Phenylketonuria: by Treatment(USD Million)
  • Table 140. Phenylketonuria Drug Therapy , by Region USD Million (2019-2024)
  • Table 141. Phenylketonuria Dietary Therapy , by Region USD Million (2019-2024)
  • Table 142. Phenylketonuria Gene Therapy , by Region USD Million (2019-2024)
  • Table 143. Phenylketonuria: by Test(USD Million)
  • Table 144. Phenylketonuria Diagnostic Test , by Region USD Million (2019-2024)
  • Table 145. Phenylketonuria Screening Test , by Region USD Million (2019-2024)
  • Table 146. Phenylketonuria: by End User(USD Million)
  • Table 147. Phenylketonuria Household , by Region USD Million (2019-2024)
  • Table 148. Phenylketonuria Hospital , by Region USD Million (2019-2024)
  • Table 149. Phenylketonuria Others , by Region USD Million (2019-2024)
  • Table 150. South America Phenylketonuria, by Country USD Million (2019-2024)
  • Table 151. South America Phenylketonuria, by Type USD Million (2019-2024)
  • Table 152. South America Phenylketonuria, by Treatment USD Million (2019-2024)
  • Table 153. South America Phenylketonuria, by Test USD Million (2019-2024)
  • Table 154. South America Phenylketonuria, by End User USD Million (2019-2024)
  • Table 155. Brazil Phenylketonuria, by Type USD Million (2019-2024)
  • Table 156. Brazil Phenylketonuria, by Treatment USD Million (2019-2024)
  • Table 157. Brazil Phenylketonuria, by Test USD Million (2019-2024)
  • Table 158. Brazil Phenylketonuria, by End User USD Million (2019-2024)
  • Table 159. Argentina Phenylketonuria, by Type USD Million (2019-2024)
  • Table 160. Argentina Phenylketonuria, by Treatment USD Million (2019-2024)
  • Table 161. Argentina Phenylketonuria, by Test USD Million (2019-2024)
  • Table 162. Argentina Phenylketonuria, by End User USD Million (2019-2024)
  • Table 163. Rest of South America Phenylketonuria, by Type USD Million (2019-2024)
  • Table 164. Rest of South America Phenylketonuria, by Treatment USD Million (2019-2024)
  • Table 165. Rest of South America Phenylketonuria, by Test USD Million (2019-2024)
  • Table 166. Rest of South America Phenylketonuria, by End User USD Million (2019-2024)
  • Table 167. Asia Pacific Phenylketonuria, by Country USD Million (2019-2024)
  • Table 168. Asia Pacific Phenylketonuria, by Type USD Million (2019-2024)
  • Table 169. Asia Pacific Phenylketonuria, by Treatment USD Million (2019-2024)
  • Table 170. Asia Pacific Phenylketonuria, by Test USD Million (2019-2024)
  • Table 171. Asia Pacific Phenylketonuria, by End User USD Million (2019-2024)
  • Table 172. China Phenylketonuria, by Type USD Million (2019-2024)
  • Table 173. China Phenylketonuria, by Treatment USD Million (2019-2024)
  • Table 174. China Phenylketonuria, by Test USD Million (2019-2024)
  • Table 175. China Phenylketonuria, by End User USD Million (2019-2024)
  • Table 176. Japan Phenylketonuria, by Type USD Million (2019-2024)
  • Table 177. Japan Phenylketonuria, by Treatment USD Million (2019-2024)
  • Table 178. Japan Phenylketonuria, by Test USD Million (2019-2024)
  • Table 179. Japan Phenylketonuria, by End User USD Million (2019-2024)
  • Table 180. India Phenylketonuria, by Type USD Million (2019-2024)
  • Table 181. India Phenylketonuria, by Treatment USD Million (2019-2024)
  • Table 182. India Phenylketonuria, by Test USD Million (2019-2024)
  • Table 183. India Phenylketonuria, by End User USD Million (2019-2024)
  • Table 184. South Korea Phenylketonuria, by Type USD Million (2019-2024)
  • Table 185. South Korea Phenylketonuria, by Treatment USD Million (2019-2024)
  • Table 186. South Korea Phenylketonuria, by Test USD Million (2019-2024)
  • Table 187. South Korea Phenylketonuria, by End User USD Million (2019-2024)
  • Table 188. Taiwan Phenylketonuria, by Type USD Million (2019-2024)
  • Table 189. Taiwan Phenylketonuria, by Treatment USD Million (2019-2024)
  • Table 190. Taiwan Phenylketonuria, by Test USD Million (2019-2024)
  • Table 191. Taiwan Phenylketonuria, by End User USD Million (2019-2024)
  • Table 192. Australia Phenylketonuria, by Type USD Million (2019-2024)
  • Table 193. Australia Phenylketonuria, by Treatment USD Million (2019-2024)
  • Table 194. Australia Phenylketonuria, by Test USD Million (2019-2024)
  • Table 195. Australia Phenylketonuria, by End User USD Million (2019-2024)
  • Table 196. Rest of Asia-Pacific Phenylketonuria, by Type USD Million (2019-2024)
  • Table 197. Rest of Asia-Pacific Phenylketonuria, by Treatment USD Million (2019-2024)
  • Table 198. Rest of Asia-Pacific Phenylketonuria, by Test USD Million (2019-2024)
  • Table 199. Rest of Asia-Pacific Phenylketonuria, by End User USD Million (2019-2024)
  • Table 200. Europe Phenylketonuria, by Country USD Million (2019-2024)
  • Table 201. Europe Phenylketonuria, by Type USD Million (2019-2024)
  • Table 202. Europe Phenylketonuria, by Treatment USD Million (2019-2024)
  • Table 203. Europe Phenylketonuria, by Test USD Million (2019-2024)
  • Table 204. Europe Phenylketonuria, by End User USD Million (2019-2024)
  • Table 205. Germany Phenylketonuria, by Type USD Million (2019-2024)
  • Table 206. Germany Phenylketonuria, by Treatment USD Million (2019-2024)
  • Table 207. Germany Phenylketonuria, by Test USD Million (2019-2024)
  • Table 208. Germany Phenylketonuria, by End User USD Million (2019-2024)
  • Table 209. France Phenylketonuria, by Type USD Million (2019-2024)
  • Table 210. France Phenylketonuria, by Treatment USD Million (2019-2024)
  • Table 211. France Phenylketonuria, by Test USD Million (2019-2024)
  • Table 212. France Phenylketonuria, by End User USD Million (2019-2024)
  • Table 213. Italy Phenylketonuria, by Type USD Million (2019-2024)
  • Table 214. Italy Phenylketonuria, by Treatment USD Million (2019-2024)
  • Table 215. Italy Phenylketonuria, by Test USD Million (2019-2024)
  • Table 216. Italy Phenylketonuria, by End User USD Million (2019-2024)
  • Table 217. United Kingdom Phenylketonuria, by Type USD Million (2019-2024)
  • Table 218. United Kingdom Phenylketonuria, by Treatment USD Million (2019-2024)
  • Table 219. United Kingdom Phenylketonuria, by Test USD Million (2019-2024)
  • Table 220. United Kingdom Phenylketonuria, by End User USD Million (2019-2024)
  • Table 221. Netherlands Phenylketonuria, by Type USD Million (2019-2024)
  • Table 222. Netherlands Phenylketonuria, by Treatment USD Million (2019-2024)
  • Table 223. Netherlands Phenylketonuria, by Test USD Million (2019-2024)
  • Table 224. Netherlands Phenylketonuria, by End User USD Million (2019-2024)
  • Table 225. Rest of Europe Phenylketonuria, by Type USD Million (2019-2024)
  • Table 226. Rest of Europe Phenylketonuria, by Treatment USD Million (2019-2024)
  • Table 227. Rest of Europe Phenylketonuria, by Test USD Million (2019-2024)
  • Table 228. Rest of Europe Phenylketonuria, by End User USD Million (2019-2024)
  • Table 229. MEA Phenylketonuria, by Country USD Million (2019-2024)
  • Table 230. MEA Phenylketonuria, by Type USD Million (2019-2024)
  • Table 231. MEA Phenylketonuria, by Treatment USD Million (2019-2024)
  • Table 232. MEA Phenylketonuria, by Test USD Million (2019-2024)
  • Table 233. MEA Phenylketonuria, by End User USD Million (2019-2024)
  • Table 234. Middle East Phenylketonuria, by Type USD Million (2019-2024)
  • Table 235. Middle East Phenylketonuria, by Treatment USD Million (2019-2024)
  • Table 236. Middle East Phenylketonuria, by Test USD Million (2019-2024)
  • Table 237. Middle East Phenylketonuria, by End User USD Million (2019-2024)
  • Table 238. Africa Phenylketonuria, by Type USD Million (2019-2024)
  • Table 239. Africa Phenylketonuria, by Treatment USD Million (2019-2024)
  • Table 240. Africa Phenylketonuria, by Test USD Million (2019-2024)
  • Table 241. Africa Phenylketonuria, by End User USD Million (2019-2024)
  • Table 242. North America Phenylketonuria, by Country USD Million (2019-2024)
  • Table 243. North America Phenylketonuria, by Type USD Million (2019-2024)
  • Table 244. North America Phenylketonuria, by Treatment USD Million (2019-2024)
  • Table 245. North America Phenylketonuria, by Test USD Million (2019-2024)
  • Table 246. North America Phenylketonuria, by End User USD Million (2019-2024)
  • Table 247. United States Phenylketonuria, by Type USD Million (2019-2024)
  • Table 248. United States Phenylketonuria, by Treatment USD Million (2019-2024)
  • Table 249. United States Phenylketonuria, by Test USD Million (2019-2024)
  • Table 250. United States Phenylketonuria, by End User USD Million (2019-2024)
  • Table 251. Canada Phenylketonuria, by Type USD Million (2019-2024)
  • Table 252. Canada Phenylketonuria, by Treatment USD Million (2019-2024)
  • Table 253. Canada Phenylketonuria, by Test USD Million (2019-2024)
  • Table 254. Canada Phenylketonuria, by End User USD Million (2019-2024)
  • Table 255. Mexico Phenylketonuria, by Type USD Million (2019-2024)
  • Table 256. Mexico Phenylketonuria, by Treatment USD Million (2019-2024)
  • Table 257. Mexico Phenylketonuria, by Test USD Million (2019-2024)
  • Table 258. Mexico Phenylketonuria, by End User USD Million (2019-2024)
  • Table 259. Research Programs/Design for This Report
  • Table 260. Key Data Information from Secondary Sources
  • Table 261. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Phenylketonuria: by Type USD Million (2013-2018)
  • Figure 5. Global Phenylketonuria: by Treatment USD Million (2013-2018)
  • Figure 6. Global Phenylketonuria: by Test USD Million (2013-2018)
  • Figure 7. Global Phenylketonuria: by End User USD Million (2013-2018)
  • Figure 8. South America Phenylketonuria Share (%), by Country
  • Figure 9. Asia Pacific Phenylketonuria Share (%), by Country
  • Figure 10. Europe Phenylketonuria Share (%), by Country
  • Figure 11. MEA Phenylketonuria Share (%), by Country
  • Figure 12. North America Phenylketonuria Share (%), by Country
  • Figure 13. Global Phenylketonuria share by Players 2018 (%)
  • Figure 14. Global Phenylketonuria share by Players (Top 3) 2018(%)
  • Figure 15. Global Phenylketonuria share by Players (Top 5) 2018(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Agios Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Agios Pharmaceuticals Inc. (United States) Revenue: by Geography 2018
  • Figure 19. BioMarin Pharmaceutical Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. BioMarin Pharmaceutical Inc. (United States) Revenue: by Geography 2018
  • Figure 21. Nestlé Health Science (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. Nestlé Health Science (Switzerland) Revenue: by Geography 2018
  • Figure 23. American Gene Technologies International Inc (United States) Revenue, Net Income and Gross profit
  • Figure 24. American Gene Technologies International Inc (United States) Revenue: by Geography 2018
  • Figure 25. Mead Johnson & Company, LLC. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Mead Johnson & Company, LLC. (United States) Revenue: by Geography 2018
  • Figure 27. Danone Nutricia (Netherlands) Revenue, Net Income and Gross profit
  • Figure 28. Danone Nutricia (Netherlands) Revenue: by Geography 2018
  • Figure 29. Ajinomoto Cambrooke, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Ajinomoto Cambrooke, Inc. (United States) Revenue: by Geography 2018
  • Figure 31. Dr. Schär (Italy) Revenue, Net Income and Gross profit
  • Figure 32. Dr. Schär (Italy) Revenue: by Geography 2018
  • Figure 33. Promin Metabolics (United States) Revenue, Net Income and Gross profit
  • Figure 34. Promin Metabolics (United States) Revenue: by Geography 2018
  • Figure 35. PKU Perspectives (United States) Revenue, Net Income and Gross profit
  • Figure 36. PKU Perspectives (United States) Revenue: by Geography 2018
  • Figure 37. Global Phenylketonuria: by Type USD Million (2019-2024)
  • Figure 38. Global Phenylketonuria: by Treatment USD Million (2019-2024)
  • Figure 39. Global Phenylketonuria: by Test USD Million (2019-2024)
  • Figure 40. Global Phenylketonuria: by End User USD Million (2019-2024)
  • Figure 41. South America Phenylketonuria Share (%), by Country
  • Figure 42. Asia Pacific Phenylketonuria Share (%), by Country
  • Figure 43. Europe Phenylketonuria Share (%), by Country
  • Figure 44. MEA Phenylketonuria Share (%), by Country
  • Figure 45. North America Phenylketonuria Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Agios Pharmaceuticals Inc. (United States)
  • BioMarin Pharmaceutical Inc. (United States)
  • Nestlé Health Science (Switzerland)
  • American Gene Technologies International Inc (United States)
  • Mead Johnson & Company, LLC. (United States)
  • Danone Nutricia (Netherlands)
  • Ajinomoto Cambrooke, Inc. (United States)
  • Dr. Schär (Italy)
  • Promin Metabolics (United States)
  • PKU Perspectives (United States)
Additional players considered in the study are as follows:
Censa Pharmaceuticals Inc. (United States) , Erytech Pharma SA (France)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation